PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Negative EBIT growth while TRAW is at 27.47%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
5.86%
Operating income growth under 50% of TRAW's 27.47%. Michael Burry would be concerned about deeper cost or sales issues.
-142.73%
Negative net income growth while TRAW stands at 27.45%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-120.58%
Negative EPS growth while TRAW is at 27.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-120.58%
Negative diluted EPS growth while TRAW is at 27.47%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.21%
Share count expansion well above TRAW's 0.03%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.21%
Diluted share count expanding well above TRAW's 0.03%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.39%
OCF growth at 50-75% of TRAW's 14.01%. Martin Whitman would question if the firm lags in monetizing sales effectively.
9.37%
FCF growth 50-75% of TRAW's 14.01%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
Negative 10Y OCF/share CAGR while TRAW stands at 2.13%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-5186.83%
Negative 5Y OCF/share CAGR while TRAW is at 2.13%. Joel Greenblatt would question the firm’s operational model or cost structure.
-34380.15%
Negative 3Y OCF/share CAGR while TRAW stands at 2.13%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-67208.18%
Negative 10Y net income/share CAGR while TRAW is at 14.09%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-8163.79%
Negative 5Y net income/share CAGR while TRAW is 14.09%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-121.82%
Negative 3Y CAGR while TRAW is 14.09%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
31995.75%
Equity/share CAGR of 31995.75% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
9371.92%
Equity/share CAGR of 9371.92% while TRAW is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
10880.98%
Equity/share CAGR of 10880.98% while TRAW is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
28.45%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
-51.38%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.21%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-6.73%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.